BioGenerator creates, grows and invests in promising bioscience companies and entrepreneurs. Our portfolio consists of staged investments, where increasing amounts of capital are deployed in the most promising companies. In addition to investments, BioGenerator supports promising early stage opportunities through grants.
Accuronix Therapeutics is developing breakthrough treatments for the most difficult types of cancer. With a particular focus in pancreatic cancer, the company’s mission is to develop novel oncology therapies founded on technology that selectively targets overexpressed receptors on cancer cells.Sector: Therapeutics ×
Adarza BioSystems is a label-free platform technology that enables the simultaneous detection of hundreds of proteins in a single drop of blood—at an industry-leading low cost. The company has developed the only next generation immunoassay platform proven capable of sensitive and reproducible highly multiplexed protein detection. BioGenerator recruited Adarza to St. Louis and was its first institutional investor.×
Aggio aspires to Transform the Agriculture Industry by developing a specialized SaaS business platform which turns data into action.
Arch Innotek produces high-value natural ingredients for human and animal health by low-cost, sustainable fermentation-based processes.×
Arch Oncology is developing humanized anti-CD47 monoclonal antibodies for multiple human diseases that will benefit from modulation of CD47 activity. BioGenerator was the company’s first investor, working with the management team to pivot to oncology and develop unique composition of matter.×
Atomation is developing an IOT platform of SHDK (software & hardware development kit) for the seamless creation of smart objects×
BacterioScan is commercializing electro-optic instruments and disposables for rapidly detecting and measuring the concentration and growth of bacteria in fluids for research and medical diagnostic applications. The technology will reduce the cost and delay of UTI diagnosis, and is expected to also reduce the unwarranted use of antibiotics.×
Benson Hill Biosystems is an agricultural biotechnology company focused on developing biotech-based traits to increase intrinsic crop yields, principally by enhancing photosynthetic efficiency. BioGenerator recruited the company to St. Louis and was its first institutional investor.×
Canopy Biosciences is a source for cutting edge research tools for genetic engineering, molecular biology, and personalized medicine. It partners with leading researchers at top institutions to turn their discoveries into tangible products, and make them available to the world. BioGenerator created Canopy Biosciences and was its first investor.Sector: Research Tools ×
Cardialen is revolutionizing atrial and ventricular disease treatment by offering a low energy therapy, released from an implantable device. BioGenerator led the company’s first financing.×
Cofactor Genomics is the market leader in RNA based products and services in the rapidly expanding functional genomics market.
Visit the Cofactor Genomics websiteSector: Contract Research Organization ×
Courier is developing targeted next-generation cytokines.×
CoverCress is developing Field Pennycress to be the next major crop in the Midwest. Pennycress produces economically important meal and oil, while providing winter cover crop benefits by preventing soil erosion and protecting from nitrogen runoff. BioGenerator worked with the founders to create CoverCress and was its first institutional investor.×
Edison Agrosciences is an agricultural biotechnology company dedicated to developing and commercializing innovative solutions for the production of plant-based industrial materials, with a primary focus on the development of alternative rubber crops.×
Electrochaea developing a game-changing technology for grid-scale energy storage by partnering with leading utilities and grid operators in Europe.×
ePharmix offers a portfolio of prescribable, disease-specific communication tools designed by practicing providers to improve their patients’ health. BioGenerator was the lead investor at the inception of the company.×
Euclises is developing patient stratified, novel, oral drugs for the treatment of COX-2 activated, refractory and resistant cancers.×
Euphrates Vascular has developed a new approach to improve the fluid dynamics in poor to zero flow vascular anatomical locations, with potential application in stroke and DVT.×
Galera Therapeutics is focused on the development of breakthrough drugs targeting the oxygen metabolic pathways. The company’s lead compounds are small molecule dismutase mimetics which prevent radiation-induced toxicity, and may also be used for treatment of fibrotic diseases and cancer. BioGenerator led Galera’s first financing, launching the company.×
Molecular diagnostics for cancer and GI diseases.
BioGenerator is an investor in Geneoscopy through its affiliate fund, Synchrony Bio.×
GeneriCo is developing and marketing generic pharmaceuticals in significant specialty segments of the rapidly growing generic drug market.×
Immunophotonics is developing an in situ therapeutic cancer vaccine for the treatment of solid tumor cancers. The technology is practical, cost-effective, nontoxic and potentially highly effective, as indicated by nonclinical and initial clinical studies.×
Impetus is developing new technology to combat insects in food crops. BioGenerator is a co-founder and seed stage investor in the company.Sector: Agriculture ×
Indalo Therapeutics is a preclinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating fibrotic diseases. Indalo is harnessing the collective experience of a seasoned team of pharmaceutical scientists and executives to tackle some of the most urgent unmet medical needs in the fibrosis space. BioGenerator worked with the founders to launch the company and was its first investor.×
Katalyst Surgical is an industry leader in titanium ophthalmic surgical instruments, and ophthalmic eye instruments.×
Kogent Surgical is a designer and manufacturer of neurosurgery titanium instruments, mono/bipolar RF Generators, true non-stick bipolar forceps, ultrasonic aspirators with true bone removal capability, and other important novel tools and devices.×
Kypha is a medical diagnostics startup developing products to improve the way inflammation and autoimmune diseases are monitored and treated. Kypha is advancing its point-of-care diagnostics platform toward regulatory clearance and market launch.×
MediBeacon is a medical device company focused on providing critical, real-time renal information to clinicians to measurably improve patient care. MediBeacon’s Optical Renal Function Monitor allows for real-time monitoring of kidney function at the point of care, providing direct, accurate, and current information. BioGenerator worked with the founders to launch the company and was its first investor.×
Mobius Therapeutics has developed a novel, patent protected kit system, Mitosol®, for delivering mitomycin-c in glaucoma, surface ablation, and pterygium surgeries. Mobius obtained FDA approval for glaucoma surgery through a 505(b)(2) NDA process and is pursuing sNDA’s for additional indications.×
Neurolutions seeks to develop a revolutionary platform of devices, based on Brain Computer Interface technology, which promise to restore function to patients who are disabled as a result of neurological injury.×
Research tools and diagnostics device.
BioGenerator is an investor in OpenCell through its affiliate fund, Synchrony Bio.×
Plastomics is a biotechnology start-up using precision engineering to develop high performance crops.×
PMDI is a partnership between the Peter Michael Foundation and The Genome Institute at Washington University School of Medicine that will commercialize breakthrough research for prostate cancer.Sector: Diagnostics ×
Readout is a digital health company with a mission to help patients better manage their own health by providing novel, clinically-backed tools to easily measure health biomarkers.
RNAgri is a startup making huge progress in RNA production and RNAi products. RNAi, which is an abbreviation for RNA interference, is a technology that relies on gene regulation without the heritable effects of DNA. Because RNAi works downstream from DNA, it is not genetic modification and therefore is non-GMO. RNAgri has developed technology that will allow the cost efficient production of RNA for broad acre topical RNAi uses in agriculture.×
S4 Agtech uses satellite images of farm fields around the world and data analytics to help its customers predict crop yields, allowing them to make more informed decisions and better allocate their resources.×
SentiAR is developing augmented reality technology to improve medical procedures. BioGenerator worked alongside the inventors at the founding of the company and then led its first financing of $2M.×
Start Right is creating delicious, convenient breakfast foods that are packed with protein×
Synchrony Bio aims to achieve consistently superior returns in biomedical and life science ventures. BioGenerator created Synchrony Bio and led its first financing.Sector: Diagnostics ×
Unleash is an immune-oncology company developing virus immunotherapy products to treat cancer.×
VaxNewMo is glycoengineering next-gen bioconjugate vaccines.×
Wealth builds brand capital by buying, investing and growing high potential under-capitalized, under-managed CPG brands that have a health, wellness or well-being benefit.×
Apertus Pharmaceuticals specializes in the manufacturing of Active Pharmaceutical Intermediates for Class II-V controlled substances. It also has related business streams for Drug Discovery Services and Analytical Services that leverage internal expertise and capabilities.×
APT Therapeutics is a potential new treatment for acute thrombotic diseases with a combination of potent anti-thrombotic and anti-inflammatory efficacy, fast onset of action, and no bleeding.×
Array Bridge provides products and services that address two important areas in the development of biologics: biosimilar and innovator drug comparability analysis and impurity analysis.×
BlueStrata assists our customers in fully implementing an EHR system while improving the quality of resident care and increasing operational, administrative and financial performance.Sector: Health IT ×
Confluence Discovery Technologies is a drug discovery and development contract research organization providing biochemistry, biomarker, target validation and other services to pharma and academic clients.×
Confluence Life Sciences is a drug discovery and development company focusing on rational drug design to identify proprietary, mechanistically novel drugs. The company has developed a portfolio of projects to address unmet medical needs in cancer and chronic inflammatory diseases.×
SynerZ Medical is a medical device company focused on the treatment of obesity, type 2 diabetes and other metabolic syndromes.
Sector: Medical Devices ×
Therapeutic antibodies for autoinflammatory disease and cancerSector: Therapeutics ×
Disarm Therapeutics is developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration.×
Provetis is a collaboration of leading scientists and commercialization experts to create new veterinary drugs and products for companion and production animals.Sector: Other ×